2UZS

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer (AKT1-PH_E17K)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.46 Å
  • R-Value Free: 0.286 
  • R-Value Work: 0.207 
  • R-Value Observed: 0.211 

wwPDB Validation 3D Report Full Report


This is version 1.4 of the entry. See complete history


Literature

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Carpten, J.D.Faber, A.L.Horn, C.Donoho, G.P.Briggs, S.L.Robbins, C.M.Hostetter, G.Boguslawski, S.Moses, T.Y.Savage, S.Uhlik, M.Lin, A.Du, J.Qian, Y.W.Zeckner, D.J.Tucker-Kellogg, G.Touchman, J.Patel, K.Mousses, S.Bittner, M.Schevitz, R.Lai, M.H.Blanchard, K.L.Thomas, J.E.

(2007) Nature 448: 439-444

  • DOI: 10.1038/nature05933
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Although AKT1 (v-akt murine thymoma viral oncogene homologue 1) kinase is a central member of possibly the most frequently activated proliferation and survival pathway in cancer, mutation of AKT1 has not been widely reported. Here we report the ident ...

    Although AKT1 (v-akt murine thymoma viral oncogene homologue 1) kinase is a central member of possibly the most frequently activated proliferation and survival pathway in cancer, mutation of AKT1 has not been widely reported. Here we report the identification of a somatic mutation in human breast, colorectal and ovarian cancers that results in a glutamic acid to lysine substitution at amino acid 17 (E17K) in the lipid-binding pocket of AKT1. Lys 17 alters the electrostatic interactions of the pocket and forms new hydrogen bonds with a phosphoinositide ligand. This mutation activates AKT1 by means of pathological localization to the plasma membrane, stimulates downstream signalling, transforms cells and induces leukaemia in mice. This mechanism indicates a direct role of AKT1 in human cancer, and adds to the known genetic alterations that promote oncogenesis through the phosphatidylinositol-3-OH kinase/AKT pathway. Furthermore, the E17K substitution decreases the sensitivity to an allosteric kinase inhibitor, so this mutation may have important clinical utility for AKT drug development.


    Organizational Affiliation

    Division of Integrated Cancer Genomics, Translational Genomics Research Institute, 445 N. Fifth Street, Phoenix, Arizona 85004, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
RAC-alpha serine/threonine-protein kinase
A
125Homo sapiensMutation(s): 1 
Gene Names: AKT1PKBRAC
EC: 2.7.11.1
Find proteins for P31749 (Homo sapiens)
Go to UniProtKB:  P31749
NIH Common Fund Data Resources
PHAROS  P31749
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
4IP
Query on 4IP

Download CCD File 
A
INOSITOL-(1,3,4,5)-TETRAKISPHOSPHATE
C6 H16 O18 P4
CIPFCGZLFXVXBG-CNWJWELYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.46 Å
  • R-Value Free: 0.286 
  • R-Value Work: 0.207 
  • R-Value Observed: 0.211 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 79.299α = 90
b = 32.711β = 116.67
c = 41.983γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
DENZOdata reduction
SCALEPACKdata scaling
AMoREphasing

Structure Validation

View Full Validation Report



Entry History 

Revision History 

  • Version 1.0: 2007-07-17
    Type: Initial release
  • Version 1.1: 2011-05-08
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2018-10-24
    Changes: Data collection, Database references, Source and taxonomy, Structure summary
  • Version 1.4: 2019-05-08
    Changes: Data collection, Derived calculations, Experimental preparation